6Snelders E, Karawajczyk A, Schaftenaar G, et al. Azole resistance profile of amino acid changes in AspergiUus fumigatus CYP51A based on protein homology modeling [J]. Antimierob Agents Che- mother, 2010, 54(6): 2425-2430.
7Lamb DC, Kelly DE, White TC, et al. The R467K amino acid substi- tution in Candida albicaru sterol 14alpha-demethylase causes drug resistance through reduced afl-mity [J]. Autimicrob Agents Chemoth- er, 2000, 44(1): 63-67.
8Chau AS, Mendrick CA, Sabatelli F J, et al. Application of real-time quantitative PCR to molecular analysis of Candida albican: strains exhibiting reduced susceptibility to azoles [J]. Antimicrob Agents Chemother, 2004, 48(6): 2124-2131.
9Holmes AR, Keniya MV, Ivnitski-Steele I, et al. The monoamine ox- idase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and IvlFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates [J]. Antimierob Agents Chemother, 2012, 56(3): 1508-1515.
10Vandeputte P, lscher F, Sanglard D, et al. In vivo systematic analysis of Candida albicans Zn2-Cys6 transcription factors mutants for mice organ colonization [J]. PLoS One, 2011, 6(10): e26962.
9Sundstrom P. Adhesion in Candida spp[J]. Cell Microbiol, 2002, 4(8) : 461-9.
10Samaranayake YH, Dassanayaake RS, Jayatilake JAMS, et al. Phospholipase B enzyme expression is not associated with other virulence attributes in Candida albicans isolates from pa ients with human immunodeficiency virus infection[J]. Journal of medical Microbiology, 2005,54: 583-93.
2Calabrese EC, Castellano S, Santoriello M, et al. Antifungal activity of azole compounds CPA18 and CPA109 against azole - susceptible and - resistant strains of Candida albicans [J]. The Journal of an- timicrobial chemotherapy, 2013, 68(5): 1111 - 1119.
3Warrilow AG, Mullins JG, Hull CM, et al. S279 point mutations in Candida albicans Sterol 14 - α demethylase (CYP51) reduce in vit- ro inhibition by fluconazole [J]. Antimicrobial Agents and Chemotherapy, 2012, 56(4): 2099 - 2107.
4Hoot S J, Smith AR, Brown RP, et al. An a643V amino acid substitu- tion in Upc2p contributes to azole resistance in well - characterized clinical isolates of candida albieans [J]. Antimicrobial Agents and Chemotherapy, 2011, 55(2): 940 - 942.
5Holmes AR, Keniya MV, Ivnitski - Steele I, et al. The monoamine oxidase A inhibitor clorgyline is a broad - spectrum inhibitor of fun- gal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clini- cal isolates[J]. Antimicrobial Agents and Chemotherapy, 2012, 56(3): 1508- 1515.
6Lohberger A, Coste AT, Sanglard D. Distinct roles of Candida albi- cans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence[J]. Eukaryotic Cell, 2014, 13(1): 127 - 142.
